Editorial Commentary
Molecular minimal residual disease in resected non-small cell lung cancer: “flattening the curve”
Translational Lung Cancer Research
2025;
14
(10)
:4180-4183
.
(31 October 2025)
KRAS under attack: recent advances in targeted therapies involving G12C inhibitors and XPO1 inhibition
Translational Lung Cancer Research
2025;
14
(10)
:4184-4186
.
(31 October 2025)
Original Article
Survival after wedge resection, segmentectomy and lobectomy for clinical stage IA non-small cell lung cancer: a systematic review and network meta-analysis
Translational Lung Cancer Research
2025;
14
(10)
:4187-4209
.
(31 October 2025)
Analysis of second-line therapy in patients with prior pneumonitis receiving first-line combination immunotherapy for advanced non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4210-4220
.
(31 October 2025)
Predicting the prognosis of patients with lung adenocarcinoma treated with third-generation EGFR-TKI alone using nomograms based on CT radiomic and clinicopathological factors
Translational Lung Cancer Research
2025;
14
(10)
:4221-4234
.
(31 October 2025)
Single-cell RNA profiling reveals an immunosuppressive microenvironment in EGFR double-mutant non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4235-4255
.
(31 October 2025)
Investigation of non-completion factors for durvalumab maintenance therapy in locally advanced non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4256-4267
.
(31 October 2025)
Feasibility of next-generation sequencing using bronchoscopic specimens in potentially resectable non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4268-4284
.
(31 October 2025)
Influencing factors and prediction of growth heterogeneity in solid nodule non-small cell lung cancer based on artificial intelligence: a prospective study
Translational Lung Cancer Research
2025;
14
(10)
:4285-4300
.
(31 October 2025)
Deep learning radiomics and 18F-FDG PET/CT imaging: mediastinal lymph node characteristics as predictors of metastasis in non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4301-4314
.
(31 October 2025)
Evaluation of gefitinib alone or combined with bevacizumab in patients with EGFR L858R-positive advanced non-squamous non-small cell lung cancer: an open-label, randomized, phase 2 trial (BEVA-FLFX-001) with exploratory analysis of plasma biomarkers
Translational Lung Cancer Research
2025;
14
(10)
:4315-4330
.
(31 October 2025)
Treatment intensity-dependent association between the number of oral hypoglycemic agents and insulin use and lung cancer risk in patients with type 2 diabetes
Translational Lung Cancer Research
2025;
14
(10)
:4331-4342
.
(31 October 2025)
Treatment outcome and safety of durvalumab after concurrent chemoradiation in very elderly patients with unresectable stage III non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4343-4356
.
(31 October 2025)
The prognostic importance of the pan-immune-inflammation value (PIV) in lung cancer: a systematic review and meta-analysis
Translational Lung Cancer Research
2025;
14
(10)
:4357-4370
.
(31 October 2025)
A retrospective cross-sectional study of FGFR2b alterations in Chinese patients with advanced squamous non-small cell lung cancer: prevalence, programmed death-ligand 1 co-expression patterns, and association with clinical outcomes
Translational Lung Cancer Research
2025;
14
(10)
:4371-4383
.
(31 October 2025)
Characterization of RET fusions via integrated DNA and RNA sequencing in early-stage non-small cell lung cancer: a retrospective study
Translational Lung Cancer Research
2025;
14
(10)
:4384-4397
.
(31 October 2025)
Comparative outcomes of treatment with versus without definitive thoracic radiotherapy in locally advanced inoperable non-small cell lung cancer during the immunotherapy era: a Chinese real-world study
Translational Lung Cancer Research
2025;
14
(10)
:4398-4411
.
(31 October 2025)
Doxorubicin paclitaxel in pretreated advanced small-cell lung cancer: a large real-life retrospective study
Translational Lung Cancer Research
2025;
14
(10)
:4412-4421
.
(31 October 2025)
Characteristics of patients with non-small cell lung cancer and either limited or extensive synchronous metastatic spread in Germany—a population-based cancer registry cohort study
Translational Lung Cancer Research
2025;
14
(10)
:4422-4435
.
(31 October 2025)
Overall survival and progression-free survival of patients with non-small cell lung cancer and either limited or extensive synchronous metastatic spread in Germany—a population-based cancer registry cohort study
Translational Lung Cancer Research
2025;
14
(10)
:4436-4448
.
(31 October 2025)
Association between soluble immune mediators and outcomes in patients with unresectable stage III non-small cell lung cancer treated with concurrent chemoradiotherapy followed by durvalumab
Translational Lung Cancer Research
2025;
14
(10)
:4449-4459
.
(31 October 2025)
Deciphering the potential pathogeny of rare tracheal adenoid cystic carcinoma by single-cell RNA-sequencing
Translational Lung Cancer Research
2025;
14
(10)
:4460-4474
.
(31 October 2025)
Deep learning-based classification of pleural malignancy using medical thoracoscopic images
Translational Lung Cancer Research
2025;
14
(10)
:4475-4484
.
(31 October 2025)
Incremental prognostic value of solid component volume ratio and entropy for pathological stage IA invasive lung adenocarcinoma after surgery
Translational Lung Cancer Research
2025;
14
(10)
:4485-4499
.
(31 October 2025)
SuFu somatic mutations are recognized as novel markers for genomic instability and tumor growth in lung adenocarcinoma
Translational Lung Cancer Research
2025;
14
(10)
:4500-4513
.
(31 October 2025)
Diagnostic utility of cryobiopsy for invasive mucinous lung adenocarcinoma
Translational Lung Cancer Research
2025;
14
(10)
:4514-4526
.
(31 October 2025)
Immunohistochemical analysis of p53 and LKB1 as predictive biomarkers of immune checkpoint inhibitor response in non-small cell lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4527-4540
.
(31 October 2025)
Fecal microbiota transplantation plus immune checkpoint inhibitor rechallenges in patients with advanced non-small cell lung cancer: a single-arm exploratory study
Translational Lung Cancer Research
2025;
14
(10)
:4541-4559
.
(31 October 2025)
Brief Report
Identification of a novel RSPO1-NUMT insertion in a LUAD patient cohort and the challenges and insights into NUMT detection highlighting the importance of reference genomes and population databases
Translational Lung Cancer Research
2025;
14
(10)
:4560-4570
.
(31 October 2025)
Review Article
Time toxicity in previously untreated metastatic or unresectable epidermal growth factor receptor-mutant non-small cell lung cancer: a clinical practice review
Translational Lung Cancer Research
2025;
14
(10)
:4571-4575
.
(31 October 2025)
A narrative review of imaging intratumor heterogeneity in non-small cell lung cancer: current advances
Translational Lung Cancer Research
2025;
14
(10)
:4576-4603
.
(31 October 2025)
The role of TRPA1 in lung cancer
Translational Lung Cancer Research
2025;
14
(10)
:4604-4617
.
(31 October 2025)
Neoadjuvant systemic therapy for pleural mesothelioma patients: a systematic review
Translational Lung Cancer Research
2025;
14
(10)
:4618-4627
.
(31 October 2025)
Utility of bronchoalveolar lavage in checkpoint inhibitor pneumonitis evaluation: a narrative review
Translational Lung Cancer Research
2025;
14
(10)
:4628-4637
.
(31 October 2025)
Immune-oncology-microbiome axis in lung cancer: from carcinogenesis to therapy—a narrative review
Translational Lung Cancer Research
2025;
14
(10)
:4638-4657
.
(31 October 2025)
Study Protocol
The impact of rurality, socioeconomic status, and health literacy on lung cancer screening uptake: a systematic review protocol
Translational Lung Cancer Research
2025;
14
(10)
:4658-4665
.
(31 October 2025)
Local consolidative therapy for the primary tumor in EGFR-mutant advanced non-small cell lung cancer following osimertinib plus chemotherapy: a protocol for a single-arm, open-label, phase 2 trial
Translational Lung Cancer Research
2025;
14
(10)
:4666-4674
.
(31 October 2025)
Case Report
The granulomatous pulmonary nodules induced by tislelizumab in advanced squamous NSCLC: a case report with challenging differential diagnosis
Translational Lung Cancer Research
2025;
14
(10)
:4675-4681
.
(31 October 2025)
Spontaneous regression of tumors post-chemotherapy in a patient with relapsed small cell lung cancer: a case report
Translational Lung Cancer Research
2025;
14
(10)
:4682-4687
.
(31 October 2025)
Lung adenocarcinoma with ALK deletion of exons 6–20 with response to sequential ALK inhibitors: a case report
Translational Lung Cancer Research
2025;
14
(10)
:4688-4694
.
(31 October 2025)
Pathological complete response in RET-positive non-small cell lung cancer: a case report of pralsetinib-based “sandwich” therapy
Translational Lung Cancer Research
2025;
14
(10)
:4695-4703
.
(31 October 2025)
